PMID- 36826037
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230228
IS  - 1467-3045 (Electronic)
IS  - 1467-3037 (Print)
IS  - 1467-3037 (Linking)
VI  - 45
IP  - 2
DP  - 2023 Feb 6
TI  - Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post 
      Liraglutide Treatment.
PG  - 1407-1421
LID - 10.3390/cimb45020092 [doi]
AB  - Diabetes mellitus is a chronic multisystem disease with a high global prevalence. 
      The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to 
      lower glucose levels and reduce weight. However, the mechanisms underlying the 
      benefits of liraglutide treatment in patients with type 2 diabetes mellitus 
      (T2DM) remain unclear. Twelve male patients with T2DM (pre and post liraglutide 
      treatment) and HbA1c between 8% and 11% were recruited. In the present study, a 
      two-dimensional difference gel electrophoresis (2D-DIGE) matrix-assisted laser 
      desorption/ionization-time of flight (MALDI TOF) mass spectrometric approach 
      combined with bioinformatics and network pathway analysis was used to explore the 
      urine proteomic profile. The mean age of the patients was 52.4 +/- 7.5 years. After 
      treatment with liraglutide, a statistically significant change (p < 0.006) was 
      observed in HbA1c with no significant changes in body weight or markers of 
      dyslipidemia. Two-dimensional difference gel electrophoresis identified 
      significant changes (>/=1.5-fold change, ANOVA, p </= 0.05) in 32 proteins (4 down- 
      and 28 upregulated) in liraglutide post treatment compared to the pre-treatment 
      state. Albumin, serotransferrin, metallothionein-2 (MT-2), and keratins K1 and 
      K10 were found to be upregulated after liraglutide treatment. The patients showed 
      significant improvement in glycemic control after the 12-week treatment with 
      liraglutide. The renoprotective effect of liraglutide may be linked to the 
      increased urinary abundance of MT-2 and the decreased abundance of zinc alpha 
      2-glycoprotein (ZAG) and Alpha-1 antitrypsin (alpha1-AT). More studies are needed to 
      elucidate the molecular mechanisms behind the renoprotective effects of 
      liraglutide.
FAU - Rafiullah, Mohamed
AU  - Rafiullah M
AUID- ORCID: 0000-0003-0583-3901
AD  - Strategic Center for Diabetes Research, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
FAU - Benabdelkamel, Hicham
AU  - Benabdelkamel H
AD  - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
FAU - Masood, Afshan
AU  - Masood A
AUID- ORCID: 0000-0001-8082-9326
AD  - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
FAU - Ekhzaimy, Aishah A
AU  - Ekhzaimy AA
AUID- ORCID: 0000-0002-8024-0631
AD  - Department of Medicine, College of Medicine, King Saud University, Riyadh 12211, 
      Saudi Arabia.
FAU - Musambil, Mohthash
AU  - Musambil M
AUID- ORCID: 0000-0003-2402-9628
AD  - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
FAU - Joy, Salini Scaria
AU  - Joy SS
AUID- ORCID: 0000-0002-3856-638X
AD  - Strategic Center for Diabetes Research, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
FAU - Alfadda, Assim A
AU  - Alfadda AA
AUID- ORCID: 0000-0002-4792-5188
AD  - Strategic Center for Diabetes Research, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
AD  - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud 
      University, Riyadh 12211, Saudi Arabia.
AD  - Department of Medicine, College of Medicine, King Saud University, Riyadh 12211, 
      Saudi Arabia.
LA  - eng
GR  - (Project No. 08-MED513-02)./This research project was supported by the National 
      Plan for Science, Technology and Innovation (MAARIFAH), King Abdulaziz City for 
      Science and Technology, Saudi Arabia/
PT  - Journal Article
DEP - 20230206
PL  - Switzerland
TA  - Curr Issues Mol Biol
JT  - Current issues in molecular biology
JID - 100931761
PMC - PMC9956006
OTO - NOTNLM
OT  - GLP-1 receptors agonist
OT  - liraglutide
OT  - metallothionein-2
OT  - proteomics
OT  - type 2 diabetes mellitus
OT  - zinc-alpha-2-glycoprotein
COIS- The authors declare no conflict of interest.
EDAT- 2023/02/25 06:00
MHDA- 2023/02/25 06:01
PMCR- 2023/02/06
CRDT- 2023/02/24 09:33
PHST- 2022/12/30 00:00 [received]
PHST- 2023/02/01 00:00 [revised]
PHST- 2023/02/02 00:00 [accepted]
PHST- 2023/02/24 09:33 [entrez]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/02/25 06:01 [medline]
PHST- 2023/02/06 00:00 [pmc-release]
AID - cimb45020092 [pii]
AID - cimb-45-00092 [pii]
AID - 10.3390/cimb45020092 [doi]
PST - epublish
SO  - Curr Issues Mol Biol. 2023 Feb 6;45(2):1407-1421. doi: 10.3390/cimb45020092.